Work

Home monitoring in interstitial lung diseases

Year: 2022

Type: review

Source: The Lancet Respiratory Medicine

DOI: 10.1016/s2213-2600(22)00228-4

Authors: Marlies S Wijsenbeek, Catharina C Moor, Kerri A Johannson, Peter D Jackson, Yet H Khor, Yasuhiro Kondoh, Sujeet K Rajan, Gabriela C Tabaj, Brenda E Varela, Pieter van der Wal, Richard N van Zyl-Smit, Michael Kreuter, Toby M Maher

Institutions: Erasmus MC, University of Calgary, Virginia Commonwealth University, Austin Health, Monash University, Tosei General Hospital, Bombay Hospital, Bhatia Hospital, Hospital Alemán, University of Cape Town, Groote Schuur Hospital, University Hospital Heidelberg, German Center for Lung Research, University of Southern California, Imperial College London

Language: English

Topic: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institute for Health and Care Research, Erasmus Medisch Centrum

Awards: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease, Improving clinical phenotyping of interstitial lung disease for better diagnosis and disease management

OpenAlex ID: W4301366342

FWCI: 3.688

Cites: 76

Cited by: 104

Related to: 10